Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patientss

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 403-412

  Sane, Rucha S ^a   Steinmann, Gerhard G ^b   Huang, Qihong ^a   Li, Yongmei ^a   Podila, Lalitha ^a   Mease, Kirsten ^a   Olson, Stephen ^a   Taub, Mitchell E ^a   Stern, Jerry O ^a   Nehmiz, Gerhard ^b   Böcher, Wulf O ^b   Asselah, Tarik ^c   Tweedie, Donald ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; CARRIER PROTEIN; CHOLECYSTOKININ OCTAPEPTIDE; FALDAPREVIR; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE PROTEIN; PEGINTERFERON; PLACEBO; RIBAVIRIN; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; N-((CYCLOPENTYLOXY)CARBONYL)-3-METHYLVALYL-4-((8-BROMO-7-METHOXY-2-(2-((2-METHYLPROPANOYL)AMINO)-1,3-THIAZOL-4-YL)QUINOLIN-4-YL)OXY)-N-(1-CARBOXY-2-ETHENYLCYCLOPROPYL)PROLINAMIDE; GLUCURONOSYLTRANSFERASE; N ((CYCLOPENTYLOXY)CARBONYL) 3 METHYLVALYL 4 ((8 BROMO 7 METHOXY 2 (2 ((2 METHYLPROPANOYL)AMINO) 1,3 THIAZOL 4 YL)QUINOLIN 4 YL)OXY) N (1 CARBOXY 2 ETHENYLCYCLOPROPYL)PROLINAMIDE; OLIGOPEPTIDE; THIAZOLE DERIVATIVE; UGT1A1 ENZYME;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE FLOW; BILIRUBIN BINDING; BILIRUBIN BLOOD LEVEL; BILIRUBIN METABOLISM; CELLULAR DISTRIBUTION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG TARGETING; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IC50; IN VITRO STUDY; IN VIVO STUDY; JAUNDICE; LIVER CELL; MRP2 GENE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OATP1B1 GENE; OATP1B3 GENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT; REPEATED DRUG DOSE; RHESUS MONKEY; UGT1A1 GENE; ANIMAL; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; LIVER; METABOLISM; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGY;

ANIMALS; BILIRUBIN; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DOUBLE-BLIND METHOD; GLUCURONOSYLTRANSFERASE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; HYPERBILIRUBINEMIA; LIVER; MACACA MULATTA; MULTICENTER STUDIES AS TOPIC; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; THIAZOLES;

EID: 84908133328     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218081     Document Type: Article

References (32)

1. Ah YM, Kim YM, Kim MJ, Choi YH, Park KH, Son IJ, and Kim SG (2008) Druginduced hyperbilirubinemia and the clinical influencing factors. Drug Metab Rev 40:511-537.
2. Annaert P, Ye ZW, Stieger B, and Augustijns P (2010) Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163-176.
3. Asselah T and Marcellin P (2014) Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int 34(Suppl 1):60-68.
4. Campbell SD, de Morais SM, and Xu JJ (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179-187.
5. Chang JH, Plise E, Cheong J, Ho Q, and Lin M (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting druginduced hyperbilirubinemia. Mol Pharm 10:3067-3075.
6. Chiou WJ, de Morais SM, Kikuchi R, Voorman RL, Li X, and Bow DAJ (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:276-282.
7. Chowdhury NR, Arias IM, Wolkoff AW, and Chowdhury JR (2001) Disorders of bilirubin metabolism, in The Liver: Biology and Pathobiology, Ed. 4th (Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, and Shafritz DA eds) pp 291-309, Lippincott Williams & Wilkins, Philadelphia.
8. Dieterich D, Asselah T, Guyader D, Berg T, Schuchmann M, Mauss S, Ratziu V, Ferenci P, Larrey D, and Maieron A, et al. (2014) SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. Antimicrob Agents Chemother 58:3429-3436.
9. Hashimoto K, Uchiumi T, Konno T, Ebihara T, Nakamura T, Wada M, Sakisaka S, Maniwa F, Amachi T, and Ueda K, et al. (2002) Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 36:1236-1245.
10. Jacobson IM, Asselah T, Ferenci P, Foster GR, Jensen DM, Negro F, Mantry P, Wright D, Forns X, Garcia-Samaniego J et al.; STARTverso3 Study Group (2013) STARTVerso3: a randomized, double-blind, placebo-controlled phase III trial of faldaprevir in combination with pegylated interferon alpha-2a and ribavirin in treatment-experienced patients with chronic HCV genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2013 November 1-5; Washington, DC.
11. Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Moreno C, Ouzan D, Wright M et al.; STARTVerso1 and STARTVerso2 Study Groups (2013) A pooled analysis of two randomized, double-blind, placebocontrolled phase III trials (STARTVerso1 and 2) of faldaprevir plus pegylated interferon a-2a and ribavirin in treatment-naive patients with chronic hepatitis genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2013 November 1-5; Washington, DC.
12. Kazmierczak SC, Robertson AF, Catrou PG, Briley KP, Kreamer BL, and Gourley GR (2002) Direct spectrophotometric method for measurement of bilirubin in newborns: comparison with HPLC and an automated diazo method. Clin Chem 48:1096-1097.
13. Kiser JJ, Burton JR, Jr, and Everson GT (2013) Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 10:596-606.
14. Korenblat KM and Berk PD (2005) Hyperbilirubinemia in the setting of antiviral therapy. Clin Gastroenterol Hepatol 3:303-310.
15. Lawitz E, Poordad F, Kowdley KV, Jensen D, Cohen DE, Siggelkow S, Wikstrom K, Larsen L, Menon RM, Podsadecki T et al. (2012) A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naïve HCV IL28B-CC genotype-1-infected subjects. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18-22; Barcelona, Spain.
16. Limdi JK and Hyde GM (2003) Evaluation of abnormal liver function tests. Postgrad Med J 79:307-312.
17. Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, and White PW, et al. (2011a) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114-1122.
18. Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, Moreno C, Lenz O, Meyvisch P, and Peeters M, et al. (2011b) Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 16:1021-1033.
19. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, and Schiff ER, et al.; IDEAL Study Team (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361:580-593.
20. Perico N, Cattaneo D, Bikbov B, and Remuzzi G (2009) Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 4:207-220.
21. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, and Koev G, et al. (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368:45-53.
22. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, and Telenti A; Swiss HIV Cohort Study (2005) Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 192:1381-1386.
23. Strassburg CP (2008) Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 9:703-715.
24. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, and Datsenko Y, et al. (2013a) Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 57:2143-2154.
25. Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, and Datsenko Y, et al. (2013b) Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 57:2155-2163.
26. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, and Hu W, et al. (2013) Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58:655-662.
27. Swift B, Pfeifer ND, and Brouwer KLR (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446-471.
28. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hrebícek M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, and Kenworthy KE, et al. (2012) Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519-528.
29. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, and Fattinger K (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
30. White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, and Thibeault D, et al. (2010) Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 54:4611-4618.
31. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, and Horban A, et al.; REALIZE Study Team (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417-2428.
32. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, and Humphreys WG (2005) In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33:1729-1739.